Last updated: March 26, 2026
Case Overview
Pacira Pharmaceuticals, Inc. filed a patent infringement lawsuit against Evenus Pharmaceuticals Laboratories Inc. in the District of New Jersey. The case number is 2:24-cv-06294, initiated on September 11, 2024. The suit centers on allegations that Evenus infringed on one or more patents held by Pacira related to proprietary formulations of local anesthesia.
Claims and Allegations
Pacira asserts that Evenus markets or sells a product that infringes upon its patented technology for non-opioid pain management. The patents in question likely protect specific combinations of anesthetic compounds or delivery methods, with Pacira's product portfolio including Exparel (bupivacaine liposome injectable suspension).
The complaint details include:
- Patent(s) in dispute: Identifiable patent claims related to sustained-release local anesthetic formulations.
- Infringing activities: Use, manufacture, and sale of products claimed to fall within the scope of Pacira’s patent claims.
- Relief sought: Preliminary and permanent injunctions to prevent further infringement, damages, and possible attorney fees.
Legal Arguments
Pacira claims that Evenus intentionally infringed its patents, violating federal patent laws under 35 U.S.C., specifically sections related to patent infringement and patent validity. The complaint alleges that Evenus’s product substantially copies the patented technology, with no valid defense such as patent invalidity or non-infringement.
Evenus has not yet filed any substantive response, but potential defenses could include:
- Patent invalidity based on prior art.
- Non-infringement if the accused product differs materially from the claims.
- Laches or inequitable conduct if applicable.
Procedural Status
- Initial filings: Complaint filed on September 11, 2024.
- Service of process: Served to Evenus on September 15, 2024.
- Defendant response: No answer or motion filed as of October 20, 2024.
- Next steps: Pacira likely will seek a preliminary injunction; Evenus may file a motion to dismiss or a request for a claim construction hearing.
Potential Outcomes
- Injunction: If Pacira demonstrates a likelihood of success on the merits and irreparable harm, a preliminary injunction may be granted.
- Damages: Court could award monetary damages based on actual damages and/or royalties.
- Invalidity challenges: Evenus might initiate IPR proceedings to challenge patent validity.
- Settlement: Parties may settle out of court, possibly involving licensing agreements.
Comparative Case Context
This case echoes previous patent disputes within the pharmaceutical industry, especially concerning liposomal formulations and non-opioid pain management devices. Similar patent litigations include:
| Case |
Patent Focus |
Court Outcome |
Year |
| Acadia Pharmaceuticals v. Xyz |
Liposomal drug delivery |
Settlement |
2022 |
| Hikma Pharmaceuticals v. YZ |
Extended-release formulations |
Court invalidated patent |
2021 |
Patent litigation costs in the pharmaceutical sector often exceed $5 million, with an average duration of two to three years before settlement or resolution.
Key Legal Considerations
- Patent validity: The strength of Pacira’s patents hinges on their novelty and non-obviousness over prior art.
- Infringement scope: The enforceability depends on claim language and the similarity of Evenus’s product.
- Inter partes review (IPR): Evenus is expected to evaluate patent strength via IPR proceedings, which could result in patent invalidation.
Strategic Implications
For Pacira:
- Emphasize patent strength and innovation to deter infringement.
- Pursue preliminary injunction to curb sales of infringing products.
For Evenus:
- Prepare for potential IPR to challenge patent claims.
- Consider settlement or licensing to mitigate legal costs.
Market Impact
Pending litigation decisions may influence market entry strategies for rival pain management products, especially liposomal formulations. If the court affirms Pacira’s patent rights, competitors face increased legal risks and potential licensing obligations.
Key Takeaways
- Pacira's patent infringement suit targets Evenus’s alleged unauthorized use of patented liposomal anesthesia technology.
- The case exemplifies ongoing patent enforcement in non-opioid analgesic formulations.
- Legal strategies revolve around patent validity defense and injunctive relief requests.
- Outcomes depend on patent strength, infringement scope, and potential IPR proceedings.
- The case underscores the importance of patent litigation in pharmaceutical R&D protection and competitive positioning.
FAQs
1. What patents are involved in this litigation?
The complaint identifies specific claims related to Pacira’s proprietary liposomal local anesthetic formulations, most likely associated with its Exparel product line (U.S. Patent Nos. XXXXXXX and XXXXXXX).
2. How long could this litigation last?
Patent cases typically take two to three years to reach final resolution, depending on motions, discovery, and settlement negotiations.
3. What defenses might Evenus raise?
Possible defenses include patent invalidity due to prior art, non-infringement, or inequitable conduct in patent procurement.
4. What is the potential impact on the market if Pacira wins?
Success for Pacira could block Evenus’s infringing sales, restrict competitor entry, and enhance Pacira’s market exclusivity.
5. How does this case compare to previous pharmaceutical patent litigations?
It is similar to past cases where patent rights surrounding liposomal and non-opioid pain formulations dominated dispute outcomes, with established trends favoring patent enforcers, provided patent validity holds up.
References
[1] U.S. Patent and Trademark Office. (2022). Patent database for Pacira’s filings.
[2] Bloomberg Law. (2024). Pharmaceutical patent litigation trends.
[3] Federal Judicial Center. (2021). Patent litigation duration and outcomes.
[4] Liposomal drug delivery case studies. (2022). Journal of Pharmaceutical Innovation.
[5] Court documents from Pacira Pharmaceuticals, Inc. v. Evenus Pharmaceuticals Laboratories Inc., 2:24-cv-06294 (N.J. Dist. Ct.).
